Pathological insight into 5-ht2b receptor activation in fibrosing interstitial lung diseases
(2021) In International Journal of Molecular Sciences 22(1).- Abstract
Interstitial lung disease (ILD) encompasses a heterogeneous group of more than 200 con-ditions, of which primarily idiopathic pulmonary fibrosis (IPF), idiopathic nonspecific interstitial pneumonia, hypersensitivity pneumonitis, ILD associated with autoimmune diseases and sarcoidosis may present a progressive fibrosing (PF) phenotype. Despite different aetiology and histopathological patterns, the PF-ILDs have similarities regarding disease mechanisms with self-sustaining fibrosis, which suggests that the diseases may share common pathogenetic pathways. Previous studies show an enhanced activation of serotonergic signaling in pulmonary fibrosis, and the serotonin (5-HT)2 receptors have been implicated to have important roles... (More)
Interstitial lung disease (ILD) encompasses a heterogeneous group of more than 200 con-ditions, of which primarily idiopathic pulmonary fibrosis (IPF), idiopathic nonspecific interstitial pneumonia, hypersensitivity pneumonitis, ILD associated with autoimmune diseases and sarcoidosis may present a progressive fibrosing (PF) phenotype. Despite different aetiology and histopathological patterns, the PF-ILDs have similarities regarding disease mechanisms with self-sustaining fibrosis, which suggests that the diseases may share common pathogenetic pathways. Previous studies show an enhanced activation of serotonergic signaling in pulmonary fibrosis, and the serotonin (5-HT)2 receptors have been implicated to have important roles in observed profibrotic actions. Our research findings in support by others, demonstrate antifibrotic effects with 5-HT2B receptor antagonists, alleviating several key events common for the fibrotic diseases such as myofibroblast differentiation and connective tissue deposition. In this review, we will address the potential role of 5-HT and in particular the 5-HT2B receptors in three PF-ILDs: ILD associated with systemic sclerosis (SSc-ILD), ILD associated with rheumatoid arthritis (RA-ILD) and IPF. Highlighting the converging pathways in these diseases discloses the 5-HT2B receptor as a potential disease target for PF-ILDs, which today have an urgent unmet need for therapeutic strategies.
(Less)
- author
- Löfdahl, Anna LU ; Tornling, Göran ; Wigén, Jenny LU ; Larsson-Callerfelt, Anna Karin LU ; Wenglén, Christina LU and Westergren-Thorsson, Gunilla LU
- organization
- publishing date
- 2021
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- 5-HT, 5-HT receptor antagonism, Fibrosis, ILD
- in
- International Journal of Molecular Sciences
- volume
- 22
- issue
- 1
- article number
- 225
- pages
- 19 pages
- publisher
- MDPI AG
- external identifiers
-
- pmid:33379351
- scopus:85098548371
- ISSN
- 1661-6596
- DOI
- 10.3390/ijms22010225
- language
- English
- LU publication?
- yes
- id
- b4763473-83d0-4d56-baa8-9e74ad0f0262
- date added to LUP
- 2021-01-13 12:56:33
- date last changed
- 2024-09-19 14:12:06
@article{b4763473-83d0-4d56-baa8-9e74ad0f0262, abstract = {{<p>Interstitial lung disease (ILD) encompasses a heterogeneous group of more than 200 con-ditions, of which primarily idiopathic pulmonary fibrosis (IPF), idiopathic nonspecific interstitial pneumonia, hypersensitivity pneumonitis, ILD associated with autoimmune diseases and sarcoidosis may present a progressive fibrosing (PF) phenotype. Despite different aetiology and histopathological patterns, the PF-ILDs have similarities regarding disease mechanisms with self-sustaining fibrosis, which suggests that the diseases may share common pathogenetic pathways. Previous studies show an enhanced activation of serotonergic signaling in pulmonary fibrosis, and the serotonin (5-HT)<sub>2</sub> receptors have been implicated to have important roles in observed profibrotic actions. Our research findings in support by others, demonstrate antifibrotic effects with 5-HT<sub>2B</sub> receptor antagonists, alleviating several key events common for the fibrotic diseases such as myofibroblast differentiation and connective tissue deposition. In this review, we will address the potential role of 5-HT and in particular the 5-HT<sub>2B</sub> receptors in three PF-ILDs: ILD associated with systemic sclerosis (SSc-ILD), ILD associated with rheumatoid arthritis (RA-ILD) and IPF. Highlighting the converging pathways in these diseases discloses the 5-HT<sub>2B</sub> receptor as a potential disease target for PF-ILDs, which today have an urgent unmet need for therapeutic strategies.</p>}}, author = {{Löfdahl, Anna and Tornling, Göran and Wigén, Jenny and Larsson-Callerfelt, Anna Karin and Wenglén, Christina and Westergren-Thorsson, Gunilla}}, issn = {{1661-6596}}, keywords = {{5-HT; 5-HT receptor antagonism; Fibrosis; ILD}}, language = {{eng}}, number = {{1}}, publisher = {{MDPI AG}}, series = {{International Journal of Molecular Sciences}}, title = {{Pathological insight into 5-ht<sub>2b</sub> receptor activation in fibrosing interstitial lung diseases}}, url = {{http://dx.doi.org/10.3390/ijms22010225}}, doi = {{10.3390/ijms22010225}}, volume = {{22}}, year = {{2021}}, }